These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35689623)

  • 1. Necrotizing myopathy associated with TET2-mutated myelodysplastic syndrome.
    Dietrich T; de Mornac D; Garnier A; Espitia A; Néel A; Normand A; Toquet C; Agard C
    QJM; 2022 Sep; 115(9):633-634. PubMed ID: 35689623
    [No Abstract]   [Full Text] [Related]  

  • 2. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
    Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
    Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
    Yun J; Ji YS; Jang GH; Lim SH; Kim SH; Kim CK; Bae SB; Won JH; Park SK
    Curr Issues Mol Biol; 2021 Aug; 43(2):917-931. PubMed ID: 34449560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively.
    Gackowski D; Gawronski M; Kerr C; Radivoyevitch T; Zarakowska E; Starczak M; Abakir A; Ruzov A; Maciejewski JP; Olinski R
    Haematologica; 2020 May; 105(5):e213-e215. PubMed ID: 31488558
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
    Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
    BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations.
    Jain P; Tang G; Konoplev SN; Kanagal-Shamanna R; Wang SA; Pemmaraju N; Daver N; Estrov Z
    Am J Hematol; 2016 Mar; 91(3):354-5. PubMed ID: 26437693
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
    Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
    Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mutation of tet2 gene and malignant blood disease].
    Qian XF; Shen YF; Zhang SJ; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1096-100. PubMed ID: 20723337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TET2 mutations in myelodysplasia and myeloid malignancies.
    Mullighan CG
    Nat Genet; 2009 Jul; 41(7):766-7. PubMed ID: 19557078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of JAK2 and TET2 mutations in myelodysplastic syndromes.
    Hellström-Lindberg E
    Blood Rev; 2010 Mar; 24(2):83-90. PubMed ID: 20171768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes.
    Gurnari C; Pagliuca S; Guan Y; Adema V; Hershberger CE; Ni Y; Awada H; Kongkiatkamon S; Zawit M; Coutinho DF; Zalcberg IR; Ahn JS; Kim HJ; Kim DDH; Minden MD; Jansen JH; Meggendorfer M; Haferlach C; Jha BK; Haferlach T; Maciejewski JP; Visconte V
    Blood Adv; 2022 Jan; 6(1):100-107. PubMed ID: 34768283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consequences of mutant TET2 on clonality and subclonal hierarchy.
    Hirsch CM; Nazha A; Kneen K; Abazeed ME; Meggendorfer M; Przychodzen BP; Nadarajah N; Adema V; Nagata Y; Goyal A; Awada H; Asad MF; Visconte V; Guan Y; Sekeres MA; Olinski R; Jha BK; LaFramboise T; Radivoyevitch T; Haferlach T; Maciejewski JP
    Leukemia; 2018 Aug; 32(8):1751-1761. PubMed ID: 29795413
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Quang VT; Podvin B; Desterke C; Tarfi S; Barathon Q; Badaoui B; Freynet N; Parinet V; Leclerc M; Maury S; Solary E; Selimoglu-Buet D; Duployez N; Wagner-Ballon O; Sloma I
    Haematologica; 2023 Nov; 108(11):3135-3141. PubMed ID: 37102610
    [No Abstract]   [Full Text] [Related]  

  • 14. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.
    Kosmider O; Gelsi-Boyer V; Slama L; Dreyfus F; Beyne-Rauzy O; Quesnel B; Hunault-Berger M; Slama B; Vey N; Lacombe C; Solary E; Birnbaum D; Bernard OA; Fontenay M
    Leukemia; 2010 May; 24(5):1094-6. PubMed ID: 20376084
    [No Abstract]   [Full Text] [Related]  

  • 15. Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome.
    Yun HD; Antony ML; Linden MA; Noble-Orcutt KE; Eckfeldt CE; Ustun C; Nelson AC; Sachs Z
    Leuk Res; 2020 Aug; 95():106404. PubMed ID: 32569927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: A novel TET2 mutation in a patient with refractory cytopenia with multilineage dysplasia.
    Coutinho DF; Diniz C; Filgueiras RL; Baptista RL; Ayres-Silva JP; Monte-Mór BC; Bonamino MH; Zalcberg IR
    Genet Mol Res; 2013 Nov; 12(4):5858-62. PubMed ID: 24301955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation in TET2 in myeloid cancers.
    Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
    N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation in TET2 in myeloid cancers.
    Tefferi A; Lim KH; Levine R
    N Engl J Med; 2009 Sep; 361(11):1117; author reply 1117-8. PubMed ID: 19741235
    [No Abstract]   [Full Text] [Related]  

  • 19. Overexpression of Hmga2 activates Igf2bp2 and remodels transcriptional program of Tet2-deficient stem cells in myeloid transformation.
    Bai J; Yokomizo-Nakano T; Kubota S; Sun Y; Kanai A; Iimori M; Harada H; Iwama A; Sashida G
    Oncogene; 2021 Feb; 40(8):1531-1541. PubMed ID: 33452460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired mutations in TET2 are common in myelodysplastic syndromes.
    Langemeijer SM; Kuiper RP; Berends M; Knops R; Aslanyan MG; Massop M; Stevens-Linders E; van Hoogen P; van Kessel AG; Raymakers RA; Kamping EJ; Verhoef GE; Verburgh E; Hagemeijer A; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
    Nat Genet; 2009 Jul; 41(7):838-42. PubMed ID: 19483684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.